Psychedelic Integration
Harm reduction education and integration therapy.
Harm Reduction & Integration
Available exclusively to members of our concierge practice.
Integration, Not Administration
After decades of prohibition, psychedelic medicines are undergoing rigorous clinical research for treatment-resistant mental health conditions. The evidence is mounting, but regulatory approval is still evolving.
Our role is not to provide these substances. Instead, we offer something equally valuable: expert medical support for those who choose to explore these experiences on their own.
Using a compassionate, non-directive harm-reduction approach, we help patients understand and integrate their experiences, maximizing potential benefits while minimizing risks.
Important Notice
We do not provide or prescribe psychedelics. All classical psychedelics, including psilocybin, MDMA, LSD, and DMT, remain Schedule I controlled substances under federal law.
We do not refer patients to underground providers or encourage illegal activities. Our services focus exclusively on harm reduction education and post-experience integration therapy.
The Evolving Landscape
The path to FDA approval is complex but progressing. Here's where things stand as of August 2026.
Psilocybin
Two Phase 3 trials in treatment-resistant depression met their primary endpoints in early 2026, and the FDA granted a rolling review that April. The manufacturer expects to complete its application by the end of 2026. Psilocybin remains investigational until the FDA acts. Oregon and Colorado run state-supervised programs outside the federal framework.
MDMA
The FDA did not approve the initial application for PTSD treatment in August 2024, citing concerns about trial methodology. The manufacturer resubmitted the application in August 2026, reportedly without a new Phase 3 trial. The FDA has not announced a decision date.
How We Support You
Using a compassionate, non-directive harm-reduction approach, we help patients understand and integrate their experiences.
Medical Safety Review
- Comprehensive medical evaluation
- Review of medications and drug interactions
- Psychological readiness assessment
- Cardiac testing and risk stratification
- Intentions, goals, and set/setting guidance
Integration Therapy
- Processing and meaning-making sessions
- Therapeutic support with trained clinicians
- Journaling and reflection guidance
- Translating insights into lasting change
- Ongoing psychotherapy as needed
Harm Reduction Education
- Physiological effects and risks
- Contraindications and safety protocols
- Substance testing and purity concerns
- Set and setting optimization
- Managing difficult experiences
Specialized Training
Expertise in Psychedelic Science
Our Medical Director, Dr. Paul Abramson, was an early graduate of the Certificate in Psychedelic Therapies and Research (CPTR) program at the California Institute of Integral Studies in San Francisco.
He has been involved in psychedelic science for over 20 years, and has provided support to the clinical trial team at UCSF studying group therapy combined with psilocybin sessions for demoralization in long-term AIDS survivors.
This combination of academic training, research involvement, and clinical experience informs our approach to integration therapy.
Training & Experience
CIIS Certificate
Psychedelic Therapies and Research
20+ Years
Involvement in psychedelic science
UCSF Research
Clinical trial support for psilocybin studies
A Physician to Think It Through With
Whether you're seeking integration support or harm reduction education, our team is here to help. These services are offered to members of our concierge practice, not as a standalone service. All inquiries are handled with complete discretion.